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Abstract
Background: Although the incidence of the use of life-ending drugs without explicit patient request has been 
estimated in several studies, in-depth empirical research on this controversial practice is nonexistent. Based on face-to-
face interviews with the clinicians involved in cases where patients died following such a decision in general practice in 
Belgium, we investigated the clinical characteristics of the patients, the decision-making process, and the way the 
practice was conducted.
Methods: Mortality follow-back study in 2005-2006 using the nationwide Sentinel Network of General Practitioners, a 
surveillance instrument representative of all GPs in Belgium. Standardised face-to-face interviews were conducted with 
all GPs who reported a non-sudden death in their practice, at home or in a care home, which was preceded by the use 
of a drug prescribed, supplied or administered by a physican without an explicit patient request.
Results: Of the 2690 deaths registered by the GPs, 17 were eligible to be included in the study. Thirteen interviews 
were conducted. GPs indicated that at the time of the decision all patients were without prospect of improvement, 
with persistent and unbearable suffering to a (very) high degree in nine cases. Twelve patients were judged to lack the 
competence to make decisions. GPs were unaware of their patient's end-of-life wishes in nine cases, but always 
discussed the practice with other caregivers and/or the patient's relatives. All but one patient received opioids to 
hasten death. All GPs believed that end-of-life quality had been "improved considerably".
Conclusions: The practice of using life-ending drugs without explicit patient request in general practice in Belgium 
mainly involves non-competent patients experiencing persistent and unbearable suffering whose end-of-life wishes 
can no longer be ascertained. GPs do not act as isolated decision-makers and they believe they act in the best interests 
of the patient. Advance care planning could help to inform GPs about patients' wishes prior to their loss of 
competence.
Background
Studies in several European countries have consistently
reported that a number of patients die following end-of-
life decisions which may, or are intended to, shorten life.
The use of drugs by physicians with the intention of end-
ing a patient's life without his or her explicit request is a
practice that has evoked considerable political, ethical
and public debate [1-3]. Although legally prohibited all
over the world, this practice seems to take place every-
where in modern healthcare, albeit with differences
between countries. Incidence estimates within Europe
range between 0.06% and 1.50% of all deaths with the
highest prevalence being reported in Flanders, Belgium
[4-6].
However, despite extensive debate about this practice
little is known about its conduct. In Belgium, for instance,
it is performed relatively more often among those
younger than 80, and those who were judged cognitively
incompetent [7-10], and occurs in the home and care
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home setting under the care of the general practitioner
(GP) in about half of all cases in 2001 [9,11,12].
In order to get a comprehensive picture of the last
phase of life in these cases, it is indispensable to gain
additional insight into the clinical characteristics of the
patients, the decision-making process and the perfor-
mance of the practice. Setting-specific information is also
valuable because GP-patient relationships formed over a
long period can differ notably from specialist-patient
relationships which are often short-term and take place in
acute circumstances [13].
This study will focus on the use of life-ending drugs by
GPs without explicit patient request, to gain insights into
how, why and for which patients GPs decide to end a life
in this manner.
Our research questions are:
1. What are the socio-demographical and clinical char-
acteristics of patients dying following the use of life-end-
ing drugs without explicit patient request in general
practice in Belgium?
2. Was the decision discussed with patients, family and/
or other professional caregivers?
3. Were other end-of-life decisions made and did they
precede, follow or take place jointly with the decision to
use life-ending drugs?
4. How was the practice performed?
Methods
Study design, setting and participants
In 2005 and 2006, a large-scale mortality follow-back
study was conducted to monitor end-of-life care and
decision-making in Belgium using the Sentinel Network
of General Practitioners (SENTI-MELC) study [14]. It
involved a quantitative registration study of deaths in the
practices of GPs within the Belgian Sentinel Network
which, since it was founded in 1979, has proved to be a
reliable surveillance system for a wide variety of health-
related epidemiological data [14-18] and which is repre-
sentative of all Belgian GPs in terms of age, sex and region
[18,19]. The study resulted in a robust representative
sample of non-sudden deaths (n = 1690) [10] not
restricted to a specific setting, age group or disease. The
study protocol and the first set of results are published
elsewhere [10,14,20-22].
During this registration study, we identified deceased
patients meeting the following inclusion criteria:
- aged one year or older at time of death
- death did not occur "suddenly or totally unexpect-
edly" as judged by the GP
- death occurred at home or in a care home
Based on these criteria 225 such patients were identi-
fied and a large interview study involving them was per-
formed.
For the current study, patients were included if the GP
registered that, in addition:
- death followed the use of 'a drug prescribed, sup-
plied or administered by the GP or a colleague physi-
cian with the explicit intention of hastening the end of
life'
- the decision concerning this act was made without
an explicit request from the patient.
For 17 (1.3%) out of 1362 patients who died at home or
in a care home in Belgium (Figure 1), life-ending drugs
without explicit patient request preceded death (binomial
95% CI, exact method: [0.7-2.0]), which is 2.0% of all
patients who died in these settings non-suddenly (bino-
mial 95% CI, exact method: [1.2-3.2]). In four cases which
met the criteria for inclusion interviews did not take
place; in only one of these was the GP unwilling to partic-
ipate. In total thirteen interviews were conducted.
Measurements
The interview with each GP was face-to-face and semi-
structured and included both closed-ended and open-
ended questions. Answers to open-ended questions were
written down verbatim. For all questions, there was room
to note additional information given by the GP.
Interview questions were based largely on existing
questionnaires [1,23-28] (see Table 1 for all interview top-
ics). Information about each patient's socio-demograph-
ics such as age at death, sex, level of education, and place
of death was retrieved from the SENTI-MELC registra-
tion study.
Procedure
In the SENTI-MELC registration study GPs registered
deaths weekly, using a standardised form [14]. Every two
months, the registration forms were screened for inter-
view inclusion criteria. The GPs in cases meeting these
criteria were contacted by telephone by an independent
person to request their participation in a face-to-face
interview. The interview took place at a time and place of
the GP's choice. Each interview was undertaken by two
researchers, one conducting the interview; the other
making detailed notes of the interviewees' responses.
Strict procedures were used to preserve patient ano-
nymity and physician confidentiality. Patient names were
never identifiable to the interviewers or to other mem-
bers of the research group: GPs used anonymous codes to
refer to their patients in the registration form and the
interviewers were given closed envelopes (prepared by
the independent telephone operator) to give to the GP
before each interview to make sure they referred to the
correct patient. After closing the interview study, the
GP's identity was permanently deleted from all files. The
Ethical Review Board of Brussels University Hospital
approved the study protocol.Meeussen et al. BMC Public Health 2010, 10:186
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Several procedures were used to ensure data quality
and prevent missing data. If the question to identify
patients who died following a life-ending act without
explicit request was left unanswered on the registration
form, a follow-up letter was sent to the GP. Also, to pre-
clude overburdening the GP, each had no more than one
interview per two months and the length of an interview
was estimated at a maximum of one hour. In order to pre-
vent recall bias, the interview was arranged as soon as
possible after inclusion. Data-entry was done with consis-
tency, range and skip checks, and the data were entered
twice.
Analyses
All closed-ended questions were descriptively analyzed
using SPSS 16.0 (SPSS Inc, Chicago, Ill). Results of the
study are presented both on an aggregate and on an indi-
vidual case level. Both answers to open-ended questions
and to questions for which additional information was
provided by the GPs were encoded into categories by two
researchers and/or registered as quotes.
Results
Table 2 and Additional file 1, Table S1 give an overview of
the socio-demographic, care and clinical characteristics
of patients dying following life-ending drug use without
their explicit request. Of all thirteen patients three were
aged 65 or younger at the time of death, eight died at
home and five in the care home. Six out of the thirteen
patients had been diagnosed with cancer and eleven had
suffered from at least one comorbidity within the last
three months of life. In the last week of life, all patients
were completely bedridden and incapable of self-care, all
but one were unconscious or in a coma for one or more
hours or days before death, and all experienced symp-
toms. In general, physical symptoms were reported more
often than psychological ones. The most frequently
reported physical symptoms were: lack of energy, lack of
appetite, feeling drowsy, and pain. The psychological
symptoms most frequently reported were feeling nervous
and feeling sad. For all but one patient (case n°12) the
symptoms also caused serious distress.
Figure 1 Process of interview inclusion.Meeussen et al. BMC Public Health 2010, 10:186
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Table 1: Interview topics assessed in this study
Questions on the patient's clinical and care characteristics 
during the last phase of life, assessing:
patient's main diagnosis [28]
other diseases for which the patient received treatment 
during the last three months of life [25-27]
patient's level of consciousness during the last week of life 
(not unconscious; unconscious one or more hours before 
death; unconscious one or more days before death; 
unconscious during whole week) [25-27]
time before death patient had started feeling ill and time 
before death patient was diagnosed [25-27]
number of GP contacts with the patient or with family 
regarding the patient during the last 3 months of life
the involvement of informal caregivers and/or clinical 
specialist in providing care for this patient during the last 3 
months of life
symptom burden in the last week of life using an adapted 
version of the Memorial Symptom Assessment Scale Global 
Distress Index (MSAS-GDI) [23]
functional status during the last three months of life using 
the Eastern Cooperative Oncology Group Performance 
Status Scale (ECOG) [24]
whether or not multidisciplinary palliative care services were 
involved
whether or not curative, life-prolonging or alternative 
palliative treatments could be considered that were not 
applied, and what the reasons were for not applying them 
[46]
to what extent the patient's suffering was persistent and 
unbearable and how GPs came to their judgment [46]
to what extent physical and/or psychological suffering was 
present that could not be alleviated [46]
to what extent the patient's medical situation was without 
prospect of improvement [46]
Questions on the process of the decision-making, assessing 
[1,3,4,6,25-27,47]:
The content and timing of the decision-making process:
whether or not the hastening of death was discussed with 
the patient (and reason for not discussing)
whether or not the patient was competent to make 
decisions (and reasons for incompetence)
wishes expressed by the patient concerning the termination 
of life, prior to the decision-making
involvement in the decision-making of patient's relatives, 
and other caregivers
time before death the decision was made and
GP's main considerations for doing so
Whether or not three other types of medical end-of-life 
decisions were made at the end of the patient's life and their 
sequence in time in relation to the decision to end life without 
explicit patient request:
(1) non-treatment decisions taking into account a possible 
hastening of death or with the explicit intent to hasten death
(2) intensifying alleviation of pain or other symptoms taking 
into account or co-intending the hastening of death
(3) using drugs to continuously sedate the patient until 
death
Questions on the performance of the practice, assessing [3,4]:
moment of drug administration and the circumstances 
surrounding death
drugs used to end life, time between administration of life-
ending drugs and coma, and death
persons involved in the drug administration and GP's 
presence during the period until death
estimated life shortening effect of the drugs
Table 1: Interview topics assessed in this study (Continued)Meeussen et al. BMC Public Health 2010, 10:186
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For six patients, GPs judged curative or life-prolonging
treatments to be available which were not applied for rea-
sons such as affording little chance of improvement or
risking additional suffering. In three cases it was consid-
ered that palliative treatment options were available but
they were not applied because the patient refused further
treatment or the physician judged it preferable not to
prolong treatment or the life of the patient. Multidisci-
plinary palliative home care was involved in four cases.
At the time of decision-making, the GP judged the
medical situation of all thirteen patients as without any
prospect of improvement (Additional file 2, Table S2).
Nine were considered to suffer persistently and unbear-
ably to a high or very high degree. All patients suffered
physically and/or psychologically to some degree, in ways
which could not be alleviated otherwise though one GP
deemed the patient's suffering not persistent and unbear-
able (case n°13). According to this GP 'the suffering was
kept under control by medication'; though any attempts at
improving the patient's medical situation had been futile
and ending life was 'clearly the best for him' (qualitative
additional information). In all cases GPs based their judg-
ments on observation and compassion; and in ten cases
also after conferring with patients themselves (before
they lost competence), their loved ones, or with other
professional caregivers (not shown in table).
Decision-making process
All but one patient had lost the capacity to assess their
situation and to make an informed decision about it (Fig-
ure 2). Reasons for incompetence cited were: the patient
could no longer communicate, or was severely demented,
unconscious, mentally disabled or considered too young
(not shown in figure). One patient was considered com-
petent but not able to express himself well (case n°9) and
had earlier expressed a wish not to suffer anymore
although this wish was not an explicit request to hasten
death. In this case the medical situation was judged futile
to the extent that, in the GP's view, the decision was in
the patient's best interest. The GP made the decision in
collaboration with a colleague physician and after several
discussions with the patient's children.
Nine patients were not competent to make decisions
and had not expressed an advance wish about the termi-
nation of life. Within this group, the decision to end life
was always discussed with either the relatives or a profes-
sional caregiver, and mostly with both. In one case no rel-
atives were involved because the patient no longer had
family.
In three cases the GP indicated that a wish had been
expressed on various occasions while the patient was still
competent which, although according to the GP not
explicit, bore upon life-ending e.g. 'I do not want to suffer
at the end of life' (qualitative additional information).
Nurses were involved in the decision-making in seven
cases for the purpose of exchange of information, joint
decision-making, support, or the arrangement of practi-
calities. Colleague physicians were involved in three cases
when they were asked for information, advice, support, or
to make the decision jointly. A frequent reason for lack of
discussion with a colleague physician was that there was
no need or that the situation was clear (not shown in fig-
ure).
In seven cases the GP felt influenced by the patient's
relatives when making the decision: in five the family was
supportive: 'we were on the same wavelength', 'it counts
that the family indicates it is taking too long', 'they asked
me: can't you do anything?'. In two cases the GP indicated
that the family was initially not ready to consider such a
decision, until they were confronted with the increasingly
unbearable pain and suffering of their relative (qualitative
additional information).
Additional file 3, Table S3 displays other end-of-life
decisions made in each case in a chronological manner. In
all cases the decision to end life without explicit patient
request was preceded by or made jointly with the deci-
sion to intensify symptom alleviation. Decisions to with-
hold or withdraw treatment were also made for ten
patients, often at different times. The following treat-
ments were decided to be withheld or withdrawn: the
administration of medication (n = 8); artificial hydration
or nutrition (n = 7); chemotherapy or radiotherapy (n =
3); reanimation (n = 2); a blood transfusion (n = 1); the
performance of an operation (n = 1).
In seven cases the GP decided to sedate the patient
continuously and deeply until death, and in five of these
this decision was made at the same time as the use of life-
ending drugs. While for most patients the decision to end
life was made within the last weeks or days, two GPs - in
collaboration with the patient's relatives - made it more
than one month before death. For one patient (case n°12),
the relevant drugs (morphine and dormicum) were made
available seven months prior to administration in the
event that the brain tumor made suffering unbearable
without possible alleviation which was the case in the
end. For one other patient (case n°9), the drugs were
available for several weeks before death and kept in the
patient's house, in case the relatives agreed upon on end-
ing the patient's life; the GP told them: 'it is you who has
to decide' (qualitative additional information).
Characteristics of the performance of the practice
None of the patients was competent at the time of the
administration of the drugs (Table 3). The hastening of
death involved the administration of opioids in all but
one case; seven patients received no other drug but opi-
oids, and opioids were combined with a benzodiazepine
in five other cases. A barbiturate induced death for oneMeeussen et al. BMC Public Health 2010, 10:186
http://www.biomedcentral.com/1471-2458/10/186
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Table 2: Life-ending drug use in general practice without patient's explicit request - aggregated (n = 13)
Sociodemographic characteristics * n
Age at death 1-64 years 3
65-79 years 6
≥ 80 years 4
Sex Male 8
Female 5
Educational level* Elementary or lower 2
Lower secondary 6
Higher secondary or more 4
Community of Belgium Dutch community 6
French community 7
Fixed partner at time of death Yes 6
No 7
Place of death Home 8
Care home 5
Symptom burden in the last week of life 
(MSAS-GDI) †
Physical symptoms Lack of energy 12 (6)
Pain 9 (5)
Dry mouth 8 (5)
Difficulty breathing 8 (4)
Feeling drowsy 10 (3)
Constipation 7 (2)
Lack of appetite 11 (1)
Psychological symptoms Feeling sad 7 (5)
Feeling nervous 9 (4)
Worrying 6 (4)
Feeling irritable 5 (3)
End-of-life care provision
Patient-GP encounters In last week of life (range) 1-15
In last 3 months of life (range) 6-42Meeussen et al. BMC Public Health 2010, 10:186
http://www.biomedcentral.com/1471-2458/10/186
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Clinical specialist involved in care in last 3 
months of life
None 4
Sometimes or often 9
Informal care over last 3 months of life None 1
Sometimes or often 12
Treatment goal over last 3 months of life Comfort/palliation 5
Transition to comfort/palliation 8
Consideration of curative or life-
prolonging treatments by GP ‡
Not possible anymore 7
Still possible but not applied 6
Reasons why not applied § Physician deemed chance for 
improvement too small
4
Physician wanted to end further 
suffering
4
Patient refused treatment (verbally or 
non-verbally)
2
Proxies wanted to end further 
suffering
1
Proxies were psychologically and 
physically exhausted
1
Consideration of alternative palliative 
treatments by GP ‡
Not possible anymore 10
Still possible but not applied 3
Reasons why not applied § Physician did not want to prolong 
patient's life
1
Physician wanted to end further 
suffering
2
Patient refused treatment 1
Multidisciplinary palliative home care 
team involved in last three months of life
Yes 4
No 9
* Missing values for level of education n = 1;
† Symptoms that were present during the last week before death, despite possible treatment. Between brackets: symptoms that distressed 
the patient, if present. Distress levels were measured for all but one case (patient comatose during last week) using the MSAS-GDI. 
Psychological symptoms were considered to have caused distress if patient did appear to feel this way "frequently" or "almost constantly". 
Physical symptoms were considered to have caused distress if symptom distressed the patient "quite a bit" or "very much"
‡ At the time of the decision making
§Multiple answers were possible;
Table 2: Life-ending drug use in general practice without patient's explicit request - aggregated (n = 13) (Continued)Meeussen et al. BMC Public Health 2010, 10:186
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patient (case n°10). Neuromuscular relaxants were not
used at all.
In three quarters of cases where the GP indicated opi-
oids were used to end life, they had already been adminis-
tered previously to alleviate pain or other symptoms. In
six cases, patients were already in a coma at the time the
first drug was administered and most others lapsed into a
coma within the following hours. All patients died within
three days of the first drug being administered. Three
GPs reported having technical problems during the
administration: one reported the occurrence of unex-
pected spasms (case n°7), one expected death to occur
more rapidly (case n°3), and one expected it to occur
more slowly (case n°6) (not shown in table).
In seven cases the final drug was given by the GP and in
six by a nurse (case n°3/4/5/6/7/8). For all patients for
whom death occurred in a care home a nurse adminis-
tered the drug without presence of the GP although the
GP was on call in four out of five of these cases (not
shown in table). Relatives of the patient were present dur-
ing the administering of the drug in nine cases. The esti-
mated life-shortening effect was for all but one patient
less than one month. This one patient (case n°10) had lost
all brain function several months before death and had
been held in a coma ever since (qualitative additional
information).
All GPs said that the instigation of life-ending had
improved their patients' end-of-life quality to some or to
a considerable extent.
Discussion
In this interview study, we examined the practice of life-
ending drug use without explicit patient request in thir-
teen cases in general practices in Belgium. The GPs
involved indicated that at the time of making the decision
there was no realistic prospect of improvement in the
condition of any of these patients, most of whom who
were suffering persistent and unbearable pain. Almost all
patients had lost the capacity to assess their situation and
to make decisions. In all cases the life-ending decision
Figure 2 The discussion of the decision.
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Table 3: Life-ending drug use without patient's explicit request: performance of the practice (n = 13)
n
Patient was competent at time of drug administration 0
Drugs used to end life Opioids only 7
Opioids in combination with a 
benzodiazepine
5
Barbiturate 1
In case opioids were used to 
end life (n = 12)
Use of opioids already 
administered previous to
9
life-ending practice to 
alleviate pain or other 
symptoms
Time between administration 
of (first) life-ending drug and 
coma
Patient was already in a coma 
at time of administration
6
Patient never lapsed into a 
complete coma
1
(awoke now and then)
15 minutes 1
2 hours 1
8 hours 1
1 day 1
2 days 2
Time between administration 
of (first) life-ending drug and 
death
instantly 1
20 minutes 1
90 minutes 2
3 hours 1
4 hours 1
12 hours 1
13 hours 1
1-2 days 3
2-3 days 2
Persons involved in 
administration
Person who administered the 
(last) life-ending drug
GP 7
Nurse 6
GP's presence during the 
administration of life-ending 
drugs until the time of death
Continuously 2
With short interruptions 3
Not present, but on call 6
Not present 2Meeussen et al. BMC Public Health 2010, 10:186
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was discussed with other caregivers and/or those close to
the patient and had preceded, accompanied or was fol-
lowed by at least one other end-of-life decision. All but
one patient received opioids with the explicit intention of
hastening the end of life. GPs believed without exception
that the patient's end-of-life quality had been improved
considerably by their actions.
This is the first study to report on the practice of life-
ending drug use without explicit patient request and to
provide detailed information on an individual level on
clinical characteristics during the last phase of life, on the
decision-making process and on the performance of the
practice. One major strength is that the thirteen cases
were selected from a large two-year registration study,
representative of all non-sudden deaths in the country
[10], and gathered via a nationwide Sentinel Network
representative of all GPs in Belgium. As such, the number
of patients dying non-suddenly following life-ending drug
use without explicit request in general practice (2.0%) was
very similar to estimated incidence figures described in
other studies in Belgium in 2001 (2.3%) [12]. Further-
more, the collected data are considered to be of high
quality because the cooperation of the GPs in the net-
work is optimal, because all interviews were conducted
face to face by two researchers and as soon as possible
after inclusion, and because quality control measures
were used in both the registration and the interview
study.
Finally, since the incidence of life-ending drug use has
been shown to be relatively high com pared with other
countries [4-6] this study of Belgium is of particular inter-
est.
However, because of the small sample of cases the
results have to be interpreted cautiously. Notwithstand-
i n g  t h a t  1 3  i n t e rv i e w s  o u t  o f  a  p o s s i b l e  1 7  w e r e  c o n -
ducted, the four additional interviews could probably
have provided even more insight into the nature of this
delicate practice. Also, due to the retrospective design of
the study a possible recall bias could not be excluded
entirely, or some decisions might have been interpreted
differently a posteriori. Finally, our findings remain lim-
ited to the experiences of GPs. Views of patients, their
family, and other caregivers were not studied.
The current study shows that patients who die follow-
ing the practice of life-ending drug use without explicit
request are those who suffer from incurable lingering dis-
eases and whose quality of life dwindles drastically in the
last phase. Although some patients were still fully active
and ambulatory during the third month before death,
they were all completely bedridden and incapable of self-
care in the last week of life. Their medical situation within
the final days was characterized mainly by unbearable
and persistent suffering, characterized by physical as well
as psychological symptom burden or by intermittent or
permanent unconsciousness. That being in a coma is
seen as a kind of suffering might seem inconsistent, but
this might be explained by a subjective, compassionate
interpretation GPs make at this very end of their long-
lasting relationship with the patient. As the GPs believed
without exception that their patient's end-of-life quality
had been improved considerably by taking this step, it
appears that they acted out of compassion and chose
what they believed to be the least bad option in a medi-
cally futile situation. Whether compassion alone may in
some cases justify this practice remains subject to intense
debate however [29].
Another important finding of the study is that, even
though patients did not or were not able to make an
explicit life-ending request, GPs were in many cases
unaware of their patient's wishes. This is remarkable
since 95% of the population has a regular GP in Belgium
[30] and have often built up a long-lasting relationship
over the course of many years [31,32]. An explanation
may be found in previous research that indicated that
GPs experience uncertainty about initiating end-of-life
discussions with their patients [33-35] which could mean
Other persons present during 
the administration of life-
ending drug
Professional caregivers & 
patient's relatives
2
Professional caregivers only 3
Patient's relatives only 7
No other persons present 1
GP's estimation of life-shortening effect of administration of life-
ending drugs
< 1 day 2
1-7 days 8
1-4 weeks 2
> 6 months 1
Table 3: Life-ending drug use without patient's explicit request: performance of the practice (n = 13) (Continued)Meeussen et al. BMC Public Health 2010, 10:186
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that they wait for the moment at which decision-making
becomes relevant, by which time patients may no longer
have the capacity to express their wishes themselves.
Therefore, advance care planning, i.e. communication
with patients to explore their wishes in the case that they
become unable to participate in decision-making [36],
remains a matter of great concern in current general
practice as GPs are in a key position to initiate and facili-
tate such discussions [37-40].
Although consultation rarely takes place with patients
themselves, it does occur frequently with others: GPs do
not appear to act surreptitiously or as isolated decision-
makers but to involve both other professional caregivers
and the patient's close circle in the decision-making pro-
cess. This might suggest that GPs have a need for the
exchanging of information, for consultation and advice,
and for making these decisions jointly with others. How-
ever, it should be noted that in some cases the GP felt no
need to discuss the decision with other professional care-
givers. Furthermore, it is remarkable that multidisci-
plinary palliative home care teams are not consulted
more often within the last months of these patients' lives,
even though in Belgium they are available to all GPs in
the country. The question however remains as to whether
the involvement of such teams would have led to a differ-
ent end-of-life decision.
Several of our findings further suggest that this end-of-
life practice is quite complex and that for the GPs
involved it resembles the process of intensified symptom
alleviation with a possible life-shortening effect or the
process of continuous deep sedation until death rather
than a separate and lethal act such as euthanasia. Firstly,
such decisions (symptom alleviation/sedation) were
made in all cases in addition to the explicit decision to
end the patient's life, and often at the same time. There-
fore it seems that these medications were often given
with a dual purpose: alleviating symptoms and hastening
the end of life. Secondly, death did not occur immediately
after the administration of the drugs. In a substantial
number of cases several hours or days passed by before
the patient died. This is in contradiction to what could be
e x p e c t e d  w h e r e  a  p r a c t i c e  s u c h  a s  e u t h a n a s i a  w a s
intended. Thirdly, even though there is strong evidence
that the lethal potential of opioids and sedatives is doubt-
ful and they therefore considered unsuitable agents where
the hastening of death is explicitly intended [41-43], opi-
oids, whether or not in combination with a benzodiaz-
epine, were the predominant drug used. In addition,
opioids were often already being administered to alleviate
pain and symptoms prior to the life-ending action. The
use of a neuromuscular relaxant which is noted in litera-
ture as an efficient euthanaticum with immediate life-
shortening effect [44] was not administered in any of the
reported cases. Other studies confirm that opioids are
commonly in this practice [6,45].
Conclusion
In conclusion, this study shows that the practice of life-
ending drug use without explicit patient request in gen-
eral practice often seems to be an act of compassion to
end the unbearable suffering of patients who can no lon-
ger decide for themselves. Our study provides various
indications that the line between different end-of-life
decisions is not always easy to define as the clinical con-
text of this practice leans towards the process of intensi-
fied symptom alleviation or of continuous deep sedation
until death. Although GPs are often not aware of their
patient's end-of-life wishes, they do not act as isolated
decision-makers and involve other professional caregiv-
ers and the patient's close circle in the decision. Advance
care planning could inform GPs about their patient's
wishes before the patient becomes incompetent.
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